Establishment Labs Holdings ( (ESTA) ) has released its Q3 earnings. Here is a breakdown of the information Establishment Labs Holdings presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Establishment Labs Holdings Inc. is a global medical technology company focused on enhancing women’s health and wellness, particularly in breast aesthetics and reconstruction, through innovative science and technology solutions.
In its third-quarter 2025 financial report, Establishment Labs announced a significant revenue increase and improved financial metrics, highlighting its robust performance in the breast aesthetics market.
The company reported a worldwide revenue of $53.8 million for the third quarter, marking a 33.8% increase from the previous year. This growth was driven by $11.9 million in Motiva sales in the United States. The gross margin improved to 70.1%, up from 63.9% a year ago, while the loss from operations decreased significantly to $4.0 million from $13.1 million. Additionally, the company achieved a positive Adjusted EBITDA of $1.2 million, a notable improvement from a $7.0 million loss in the same quarter last year.
Looking ahead, Establishment Labs is optimistic about its future growth, with expectations to exceed $210 million in revenue for 2025 and a strong performance in the US breast augmentation market. The company aims to achieve cash flow positivity next year, driven by its innovative minimally invasive platform and expanding market share.
Overall, Establishment Labs is poised for continued growth, leveraging its technological advancements and strategic market positioning to enhance its financial performance and market presence in the coming years.